Sage Journals: Discover world-class research

Abstract

Background

Palmoplantar pustulosis (PPP) is a rare, relapsing, disease characterized by pustules, pain, and fissuring. PPP is often combined with psoriasis, most commonly palmar plantar psoriasis, in clinical trials which further complicates our understanding of treatment response.

Objective

The objective of this scoping review is to describe all outcome measures (clinician-reported & patient-reported) used in previous PPP clinical trials.

Methods

A search was conducted in Medline, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) for clinical trials and prospective cohort studies performed in adults with PPP, with an intervention and pre-determined outcomes collected at pre specified time points.

Results

The initial search identified 1839 records, of which 69 met our inclusion criteria. The studies were published between 1970–2023 and included a total of 3301 patients. The most common primary study outcome was the clinician-reported Palmoplantar Pustulosis Psoriasis Area Severity Index (ppPASI) (n = 39, 56.5%) and an endpoint of 12 weeks (n = 23, 33.3%). Other common clinician reported outcomes identified were pustule count (n = 26, 37.7%) and the Physician Global Assessment (n = 16, 23.2%) The majority of studies (n = 43, 62.3%) did not include any patient reported outcome measures. Of those that did include patient reported outcome measures, the Dermatology Life Quality Index was most utilized (n = 17, 24.6%), followed by symptoms-specific instruments measuring pain (n = 11, 15.9%) and itch (n = 6, 8.7%).

Conclusions

While the clinician-reported ppPASI has become the standard primary outcome in PPP clinical trials, there is still considerable heterogeneity and lack of specificity in the patient reported outcomes used.

Keywords

psoriasis pustular psoriasis palmoplantar pustulosis clinician reported outcomes patient reported outcomes

Get full access to this article

View all access options for this article.

References

Yamamoto

. Extra-palmoplantar lesions associated with palmoplantar pustulosis. J Eur Acad Dermatol Venereol. 2009;23(11):1227-1232.

Obeid

Kirby

Hughes

Sbidian

Le Cleach

. Interventions for chronic palmoplantar pustulosis. Cochrane Database Syst Rev. 2020;1(1):CD011628.

Navarini

Burden

Capon

, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792-1799.

Powers

3rd Walton

, et al. Clinician-reported outcome assessments of treatment benefit: report of the ISPOR clinical outcome assessment emerging good practices task force. Value Health. 2017;20(1):2-14.

Barbieri

Gelfand

. Patient-reported outcome measures as complementary information to clinician-reported outcome measures in patients with psoriasis. JAMA Dermatol. 2021;157(10):1236-1237.

Tricco

Lillie

Zarin

, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467-473.

Jin

X-H

Chen

Mou

Xia

J-X

. Effects of cyclosporine on palmoplantar pustulosis and serum expression of IL-17, IL-23, and TNF-α. Dermatol Ther. 2019;9:547-552.

Finlay

Basra

MKA

Piguet

Salek

. Dermatology life quality index (DLQI): a paradigm shift to patient-centered outcomes. J Invest Dermatol. 2012;132(10):2464-2465.

Farley

Masrour

McKey

Menter

. Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol. 2009;60(6):1024-1031.

10.

Reilly

Zbrozek

Dukes

. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353-365.

11.

Herdman

Gudex

Lloyd

, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727-1736.

12.

Delgado

Lambert

Boutris

, et al. Validation of digital visual analog scale pain scoring with a traditional paper-based visual analog scale in adults. J Am Acad Orthop Surg Glob Res Rev. 2018;2(3):e088.

13.

Pedersen

McHorney

Larsen

Lophaven

Moeller

Reaney

. Reliability and validity of the psoriasis itch visual analog scale in psoriasis vulgaris. J Dermatol Treat. 2017;28(3):213-220.

14.

Carlin

Feldman

Krueger

Menter

Krueger

. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004;50(6):859-866.

15.

Perez-Chada

Salame

Ford

, et al. Investigator and patient global assessment measures for psoriasis clinical trials: a systematic review on measurement properties from the international dermatology outcome measures (ideom) initiative. Am J Clin Dermatol. 2020;21(3):323-338.

16.

Guidance for Industry . Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. USA: U.S. Department of Health and Human Services Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims

17.

Barbieri

Chiesa Fuxench

Shin

Takeshita

. Frequency and influence of “not relevant” responses on the Dermatology Life Quality Index among adults with atopic dermatitis. Qual Life Res. 2021;30(6):1705-1713.

18.

Langenbruch

Radtke

Gutknecht

Augustin

. Does the Dermatology Life Quality Index (DLQI) underestimate the disease-specific burden of psoriasis patients? J Eur Acad Dermatol Venereol. 2019;33(1):123-127.

19.

Rencz

Poór

Péntek

, et al. A detailed analysis of ‘not relevant' responses on the DLQI in psoriasis: potential biases in treatment decisions. J Eur Acad Dermatol Venereol. 2018;32(5):783-790.

20.

Paudyal

Apfelbacher

Jones

, et al. “DLQI seems to be ‘action', and skindex-29 seems to be ‘emotion'”: qualitative study of the perceptions of patients with psoriasis or eczema on two common dermatology-specific quality of life measures. Acta Derm Venereol. 2020;100(8):adv00105.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.26 MB